API | taliglucerase alfa

taliglucerase alfa (elelyso) Report issue

Biologics Recombinant protein Orphan Drug ^FDA Approved ^FDA Fast Track ^FDA

AACT ChEMBL DrugBank Drugs@FDA MeSH

Active Ingredient History

NOW

Taliglucerase alfa, sold under the brand name Elelyso among others, is a biopharmaceutical medication developed by Protalix and Pfizer. The drug, a recombinant glucocerebrosidase used to treat Gaucher's disease, is the first plant-made pharmaceutical to win approval by the U.S. Food and Drug Administration (FDA). Each vial has 200 units of taliglucerase alfa. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
taliglucerase alfa

More Chemistry

Pharmacology

Mechanisms of Action:
Multi-specific: No
Black Box: No
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

Drug Pricing (per unit)

United States

$581.0800 - $786.1600

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

elelyso | prgcd | taliglucerase alfa

Organizations (6)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (1)

Approved Indications (1)

Gaucher Disease

Experimental Indications - Clinical Trial Phases 1-4 (1)

Gaucher Disease ()

Overview

Highest Phase: Phase 4
# of Trials: 11
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue